Research ExplorerPublicationsFeasibility, safety, and acute efficacy of the fourth-genera...

Feasibility, safety, and acute efficacy of the fourth-generation cryoballoon for ablation of atrial fibrillation: Another step forward?

Standard

Feasibility, safety, and acute efficacy of the fourth-generation cryoballoon for ablation of atrial fibrillation: Another step forward? / Rottner, Laura; Mathew, Shibu; Reissmann, Bruno; Warneke, Laura; Martin, Isabell; Lemes, Christine; Maurer, Tilman; Wohlmuth, Peter; Ouyang, Feifan; Kuck, Karl-Heinz; Metzner, Andreas; Rillig, Andreas.

In: CLIN CARDIOL, Vol. 43, No. 4, 01.04.2020, p. 394-400.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rottner, L, Mathew, S, Reissmann, B, Warneke, L, Martin, I, Lemes, C, Maurer, T, Wohlmuth, P, Ouyang, F, Kuck, K-H, Metzner, A & Rillig, A 2020, 'Feasibility, safety, and acute efficacy of the fourth-generation cryoballoon for ablation of atrial fibrillation: Another step forward?', CLIN CARDIOL, vol. 43, no. 4, pp. 394-400. https://doi.org/10.1002/clc.23328

APA

Rottner, L., Mathew, S., Reissmann, B., Warneke, L., Martin, I., Lemes, C., Maurer, T., Wohlmuth, P., Ouyang, F., Kuck, K-H., Metzner, A., & Rillig, A. (2020). Feasibility, safety, and acute efficacy of the fourth-generation cryoballoon for ablation of atrial fibrillation: Another step forward? CLIN CARDIOL, 43(4), 394-400. https://doi.org/10.1002/clc.23328

Vancouver

Rottner L, Mathew S, Reissmann B, Warneke L, Martin I, Lemes C et al. Feasibility, safety, and acute efficacy of the fourth-generation cryoballoon for ablation of atrial fibrillation: Another step forward? CLIN CARDIOL. 2020 Apr 1;43(4):394-400. https://doi.org/10.1002/clc.23328

Bibtex

@article{ca2bb5b07ff3499aa371386d71b4c738,
title = "Feasibility, safety, and acute efficacy of the fourth-generation cryoballoon for ablation of atrial fibrillation: Another step forward?",
abstract = "BACKGROUND: The second-generation cryoballoon (CB2) is widely used for pulmonary vein (PV) isolation (PVI) in patients with paroxysmal atrial fibrillation (AF). Recently, the novel fourth-generation CB (CB-Advance PRO) was introduced, incorporating a shortened catheter tip.HYPOTHESIS: The aim of this study was to evaluate the feasibility and acute efficacy of PVI using the CB-Advance PRO.METHODS: A total of 200 consecutive patients were analyzed. Hundred patients who underwent PVI due to symptomatic, drug-refractory AF were treated with the CB-Advance PRO (group I) and were included into this multicenter analysis. A group of 100 patients were treated with the CB2 and acted as controls (group II).RESULTS: In total, 739 of 739 PVs (100%) were successfully isolated. There was a nonsignificant trend in the incidence of online registration of PV signals between both groups (group I: 77.9% vs group II: 71.4%, P = .09). Median time to PVI (time to isolation [TTI]) and mean total freezing time were significantly shorter when using the CB-Advance PRO (group I: 33 [23, 50] vs group II: 40 [26, 60] seconds and group I: 166 ± 29 vs group II: 183 ± 38 seconds, P < .01). In three of 100 (3%) patients of group I and one of 100 (1%) patients of group II, a transient phrenic nerve palsy occurred (P = .62).CONCLUSION: The use of the novel CB-Advance PRO is feasible and associated with a significant reduction in mean TTI and mean total freezing time as compared to the CB2.",
keywords = "Action Potentials, Aged, Atrial Fibrillation/diagnosis, Cardiac Catheters, Catheter Ablation/adverse effects, Cryosurgery/adverse effects, Equipment Design, Feasibility Studies, Female, Germany, Heart Rate, Humans, Male, Middle Aged, Operative Time, Postoperative Complications/etiology, Pulmonary Veins/physiopathology, Retrospective Studies, Time Factors, Treatment Outcome",
author = "Laura Rottner and Shibu Mathew and Bruno Reissmann and Laura Warneke and Isabell Martin and Christine Lemes and Tilman Maurer and Peter Wohlmuth and Feifan Ouyang and Karl-Heinz Kuck and Andreas Metzner and Andreas Rillig",
note = "{\textcopyright} 2020 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.",
year = "2020",
month = apr,
day = "1",
doi = "10.1002/clc.23328",
language = "English",
volume = "43",
pages = "394--400",
journal = "CLIN CARDIOL",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Feasibility, safety, and acute efficacy of the fourth-generation cryoballoon for ablation of atrial fibrillation: Another step forward?

AU - Rottner, Laura

AU - Mathew, Shibu

AU - Reissmann, Bruno

AU - Warneke, Laura

AU - Martin, Isabell

AU - Lemes, Christine

AU - Maurer, Tilman

AU - Wohlmuth, Peter

AU - Ouyang, Feifan

AU - Kuck, Karl-Heinz

AU - Metzner, Andreas

AU - Rillig, Andreas

N1 - © 2020 The Authors. Clinical Cardiology published by Wiley Periodicals, Inc.

PY - 2020/4/1

Y1 - 2020/4/1

N2 - BACKGROUND: The second-generation cryoballoon (CB2) is widely used for pulmonary vein (PV) isolation (PVI) in patients with paroxysmal atrial fibrillation (AF). Recently, the novel fourth-generation CB (CB-Advance PRO) was introduced, incorporating a shortened catheter tip.HYPOTHESIS: The aim of this study was to evaluate the feasibility and acute efficacy of PVI using the CB-Advance PRO.METHODS: A total of 200 consecutive patients were analyzed. Hundred patients who underwent PVI due to symptomatic, drug-refractory AF were treated with the CB-Advance PRO (group I) and were included into this multicenter analysis. A group of 100 patients were treated with the CB2 and acted as controls (group II).RESULTS: In total, 739 of 739 PVs (100%) were successfully isolated. There was a nonsignificant trend in the incidence of online registration of PV signals between both groups (group I: 77.9% vs group II: 71.4%, P = .09). Median time to PVI (time to isolation [TTI]) and mean total freezing time were significantly shorter when using the CB-Advance PRO (group I: 33 [23, 50] vs group II: 40 [26, 60] seconds and group I: 166 ± 29 vs group II: 183 ± 38 seconds, P < .01). In three of 100 (3%) patients of group I and one of 100 (1%) patients of group II, a transient phrenic nerve palsy occurred (P = .62).CONCLUSION: The use of the novel CB-Advance PRO is feasible and associated with a significant reduction in mean TTI and mean total freezing time as compared to the CB2.

AB - BACKGROUND: The second-generation cryoballoon (CB2) is widely used for pulmonary vein (PV) isolation (PVI) in patients with paroxysmal atrial fibrillation (AF). Recently, the novel fourth-generation CB (CB-Advance PRO) was introduced, incorporating a shortened catheter tip.HYPOTHESIS: The aim of this study was to evaluate the feasibility and acute efficacy of PVI using the CB-Advance PRO.METHODS: A total of 200 consecutive patients were analyzed. Hundred patients who underwent PVI due to symptomatic, drug-refractory AF were treated with the CB-Advance PRO (group I) and were included into this multicenter analysis. A group of 100 patients were treated with the CB2 and acted as controls (group II).RESULTS: In total, 739 of 739 PVs (100%) were successfully isolated. There was a nonsignificant trend in the incidence of online registration of PV signals between both groups (group I: 77.9% vs group II: 71.4%, P = .09). Median time to PVI (time to isolation [TTI]) and mean total freezing time were significantly shorter when using the CB-Advance PRO (group I: 33 [23, 50] vs group II: 40 [26, 60] seconds and group I: 166 ± 29 vs group II: 183 ± 38 seconds, P < .01). In three of 100 (3%) patients of group I and one of 100 (1%) patients of group II, a transient phrenic nerve palsy occurred (P = .62).CONCLUSION: The use of the novel CB-Advance PRO is feasible and associated with a significant reduction in mean TTI and mean total freezing time as compared to the CB2.

KW - Action Potentials

KW - Aged

KW - Atrial Fibrillation/diagnosis

KW - Cardiac Catheters

KW - Catheter Ablation/adverse effects

KW - Cryosurgery/adverse effects

KW - Equipment Design

KW - Feasibility Studies

KW - Female

KW - Germany

KW - Heart Rate

KW - Humans

KW - Male

KW - Middle Aged

KW - Operative Time

KW - Postoperative Complications/etiology

KW - Pulmonary Veins/physiopathology

KW - Retrospective Studies

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1002/clc.23328

DO - 10.1002/clc.23328

M3 - SCORING: Journal article

C2 - 32097501

VL - 43

SP - 394

EP - 400

JO - CLIN CARDIOL

JF - CLIN CARDIOL

SN - 0160-9289

IS - 4

ER -